KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• April 2023

Invasive Group B Streptococcus remains a leading cause of infant morbidity and mortality. Intrapartum antibiotic prophylaxis has been implemented in many countries with a reduction in early-onset disease, but an effective vaccine may further reduce the disease burden. Candidate vaccines targeting capsular polysaccharides and surface proteins are now in clinical trials.  ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2024
• April 2024

Children with chronic medical conditions are at increased risk of severe influenza. Uptake of influenza vaccination in children and adolescents with these identified special risk medical conditions is suboptimal. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• April 2023

Tess Gregory TG BSc (Hons), PhD (Psychology) Senior Research Fellow +61 8 6375 6113 tess.gregory@telethonkids.org.au Senior Research Fellow Tess is ...

• 1. Telethon Kids Institute
• Our research
• Brain and Behaviour
• Population Health Program
• Early Years Systems Evidence

Australian authorities made COVID-19 vaccines available for children aged under 5 years old with serious comorbidities in August 2022. There is presently no universal programme for young children, but crucial to any rollout's success is whether parents are motivated and able to vaccinate. By examining parents' vaccine intentions, this study aims to inform current and future COVID-19 vaccine roll-outs for children aged under 5 years. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• January 2023

Children with Down syndrome (DS) are at a significantly higher risk of developing acute myeloid leukemia, also termed myeloid leukemia associated with DS (ML-DS). In contrast to the highly favorable prognosis of primary ML-DS, the limited data that are available for children who relapse or who have refractory ML-DS (r/r ML-DS) suggest a dismal prognosis. There are few clinical trials and no standardized treatment approach for this population. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• February 2023

Acute Lymphoblastic Leukemia (ALL) occurring in the first year of life is rare. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2012
• September 2012

The MECP2 mutations occurring in the severe neurological disorder Rett syndrome are predominantly de novo, with rare familial cases. The aims of this study... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2012
• December 2012

This study describes patterns of hospitalisations for children and young people with Down syndrome in Western Australia. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2013
• August 2013

The transition from school to adulthood for young adults with an intellectual disability involves movement from a generally secure and supported school... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2013
• June 2013